Alkan, A. Et Al. 2021. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients. JOURNAL OF MENS HEALTH , vol.17, no.4 , 128-134.

Alkan, A., Guc, Z. G., Gurbuz, M., ozgun, G., Degirmencioglu, S., Dogan, M., ... Telli, T. A.(2021). Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients. JOURNAL OF MENS HEALTH , vol.17, no.4, 128-134.

Alkan, Ali Et Al. "Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients," JOURNAL OF MENS HEALTH , vol.17, no.4, 128-134, 2021

Alkan, Ali Et Al. "Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients." JOURNAL OF MENS HEALTH , vol.17, no.4, pp.128-134, 2021

Alkan, A. Et Al. (2021) . "Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients." JOURNAL OF MENS HEALTH , vol.17, no.4, pp.128-134.

@article{article, author={Ali Alkan Et Al. }, title={Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients}, journal={JOURNAL OF MENS HEALTH}, year=2021, pages={128-134} }